Biotech company Moderna said on Monday that early analysis from its phase 3 trial shows its Covid-19 vaccine is 94.5 percent effective at preventing infection.
The news comes a week after pharmaceutical giant Pfizer said early analysis showed its vaccine candidate was more than 90 percent effective at preventing infection.
Professor Trudie Lang, the director of the Global Health Network at Oxford University, called the second announcement “very good news indeed.”
Download the NBC News app for the latest news on the coronavirus
“These early results suggest that there was a representation across different age groups and diverse communities in the protected group,” she told Reuters. “This is really encouraging and it further demonstrates that a vaccine for Covid is a real probability and that having more than one supplier should help assure better and more equitable global availability.”
Infectious disease experts weigh in on Thanksgiving plans
This is a developing story. Check back for updates.
This content was originally published here.